{"id":251599,"date":"2024-05-17T00:00:00","date_gmt":"2024-05-17T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/products\/research-reports\/report\/epidim0068-biopharma-overactive-bladder-epidemiology-emerging\/"},"modified":"2026-03-31T10:30:06","modified_gmt":"2026-03-31T10:30:06","slug":"epidim0068-biopharma-overactive-bladder-epidemiology-emerging-markets-data","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidim0068-biopharma-overactive-bladder-epidemiology-emerging-markets-data\/","title":{"rendered":"Overactive Bladder &#8211; Epidemiology &#8211; Emerging Markets Data"},"content":{"rendered":"<p>Clarivate Epidemiology\u2019s coverage of overactive bladder (<abbr title=\"overactive bladder\">OAB<\/abbr>) comprises epidemiological estimates of key patient populations in 14 mature and emerging pharmaceutical markets worldwide. We report the total prevalence of <abbr title=\"overactive bladder\">OAB<\/abbr> for each country, as well as annualized case counts projected to the national population.<\/p>\n<p>Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report.<\/p>\n<p>Clarivate Epidemiology\u2019s <abbr title=\"overactive bladder\">OAB<\/abbr> forecast will answer the following question:<\/p>\n<ul class=\"round-bullets\">\n<li>How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of <abbr title=\"overactive bladder\">OAB<\/abbr> over the forecast period?<\/li>\n<\/ul>\n<p>All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is provided for full transparency into research and methods.<\/p>\n<p>In addition to the total number of cases for each forecast year, Clarivate Epidemiology provides at least 10 years of forecast data for the following <abbr title=\"overactive bladder\">OAB<\/abbr> subpopulations:<\/p>\n<ul class=\"round-bullets\">\n<li>Total prevalent cases by subtype.<\/li>\n<li>Total prevalent cases by severity.<\/li>\n<li>Total prevalent cases by etiology.<\/li>\n<\/ul>\n<p>Note: Coverage may vary by country.<\/p>\n","protected":false},"template":"","class_list":["post-251599","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-genitourinary","biopharma-therapy-areas-overactive-bladder","biopharma-product-epidemiology","biopharma-date-985"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251599","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251599\/revisions"}],"predecessor-version":[{"id":281005,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251599\/revisions\/281005"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=251599"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}